ClinicalTrials.gg
CompletedNCT02452931Updated Jun 2, 2020Results posted

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

A Phase 3 interventional study of Leuprolide Acetate 45 mg in Precocious Puberty, Central, sponsored by Tolmar Inc.. Completed at 20 sites in 6 countries. Open to participants aged 2 Years to 9 Years. Per ClinicalTrials.gov, last updated 2020-06-02.

Sponsored by Tolmar Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
2 Years to 9 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
8th of 14
64 · median 68
Started
2015
with 1 other
Phase 3
6 of 14
1 open now
Registered
7th of 14
by date

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 8th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 3, and was the 7th registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 2 Years to 9 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

This study determines the effectiveness of leuprolide acetate 45 mg for injectable suspension for treatment of children with Central Precocious Puberty.

Read the detailed description

Leuprolide acetate is a GnRH agonist that inhibits pituitary gonadotropin secretion by binding to the GnRH receptors and blocking downstream hormone synthesis. The steady decrease in hormone synthesis (LH and FSH) leads to a suppression of testicular and ovarian steroidogenesis. In children with CPP, this steady decrease in hormone synthesis disrupts the progression of puberty.

03

Conditions studied

  • Precocious Puberty, Central

Browse trials for

04

Who can participate

Ages eligible
2 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive)
  • Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
  • Pubertal-type LH response following an abbreviated GnRHa stimulation test before treatment initiation
  • Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males
  • Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year

Exclusion criteria

Exclusion Criteria:

  • Gonadotropin-independent (peripheral) precocious puberty
  • Prior or current GnRH treatment for CPP
  • Prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1)
  • Diagnosis of short stature (ie, 2.25 standard deviations (SD) below the mean height for age)
  • Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
  • Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Assigned Intervention

    Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.

    Drug: Leuprolide Acetate 45 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.

    Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \<4 IU/L. Peak stimulated LH refers to the maximum LH concentration measured 30 minutes after a gonadotropin-releasing hormone agonst (GnRHa) stimulation test.

    Time frame: 6 months

Secondary outcomes

  1. Percentage of Subjects With Suppression of Luteinizing Hormone Measured by Blood Levels.

    Percentage of subjects with suppressed serum LH concentrations(\<4 IU/L) 30 minutes post GnRHa stimulation test at all assessed timepoints.

    Time frame: Week 12, Week 24, Week 36, and Week 48

  2. Changes in Height Velocity (Growth Rate)

    Changes in height velocity (growth rate) at all study timepoints after Screening to end of study. Growth velocity is defined for each visit as change from baseline / \[(number of weeks since baseline)/52\]. Week 48: Change from Week 24 growth velocity is defined as change from week 24 to week 48 / \[(number of weeks since week 24)/52\].

    Time frame: Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48

  3. Bone Age Ratio to Chronological Age at Time of Measurement

    Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.

    Time frame: Week 24 and Week 48

  4. Percent Change From Baseline in Height

    The percent change from baseline in height at each available post-baseline measurement. Percent change is defined as (((change from Baseline)/(Baseline)) x 100).

    Time frame: Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48

  5. Tanner Scores: Boys - Development of External Genitalia

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48

  6. Tanner Scores: Boys - Development of External Genitalia (Change From Baseline)

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Week 12, Week 24, Week 36, and Week 48

  7. Tanner Scores: Boys and Girls - Pubic Hair

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48

  8. Tanner Scores: Boys and Girls - Pubic Hair (Change From Baseline)

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Week 12, Week 24, Week 36, and Week 48

  9. Tanner Scores: Girls - Breast Development

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Baseline, Week 12, Week 24, Week 36, and Week 48

  10. Tanner Scores: Girls - Breast Development (Change From Baseline)

    Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

    Time frame: Week 12, Week 24, Week 36, and Week 48

Other outcomes

  1. Height

    Height at each available measurement point. Baseline is defined as the last non-missing height measurement collected prior to or on the date of first injection.

    Time frame: Screening, Baseline, Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48

  2. Bone Age

    Bone Age at each available measurement point.

    Time frame: Baseline, Week 24, and Week 48

  3. Bone Age Progression

    Bone age progression at each available post-baseline measurement point. Bone age progression is defined as (((change from baseline)/(baseline)) x 100), which is percent change from baseline.

    Time frame: Week 24 and Week 48

  4. Bone Age Ratio to Chronological Age at Time of Measurement (Percent Change From Baseline)

    Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.

    Time frame: Week 24 and Week 48

  5. Bone Age Ratio to Chronological Age at Start of Study (Percent Change From Baseline)

    Bone age advancement was evaluated relative to chronological age at each given measurement point. Percent change from baseline is: 100 x (the change from baseline value at the post-baseline visit / baseline value).

    Time frame: Week 24 and Week 48

  6. Bone Age Ratio to Chronological Age at Start of Study

    Bone age advancement was evaluated relative to chronological age at each given measurement point. Bone Age Ratio to Chronological Age at Start of Study is bone age/age at first injection.

    Time frame: Baseline, Week 24, and Week 48

  7. GnRH Antagonist Evaluation

    GnRH Antagonist Evaluation occurred for the two week period following each treatment and at each visit to assess flare symptoms. The percent of subjects who affirm (or whose parent/guardian affirms) each symptom domain in the global interview.

    Time frame: Week 2, Week 4, Week 12, Week 20, Week 24, Week 26, Week 36, Week 44, and Week 48

  8. Percentage of Subjects With Suppression of FSH, Estradiol, Oestradiol (HS), and Testosterone Measured by Blood Levels.

    The percentage of subjects with FSH, estradiol and testosterone suppression to prepubertal levels (FSH \< 2.5 mIU/mL, estradiol \< 20 pg/mL and testosterone \< 28.4 ng/dL) at each available time point.

    Time frame: Week 12, Week 24, Week 36, and Week 48

  9. Changes in the Ratio of LH/FSH

    Changes in ratio of LH/FSH at each time point from Screening to End of Study

    Time frame: Screening (Pre&Post GnRHa Stim Test), Baseline (0,1,4,6 hours Post-Injection), Week 4, Week 12 (Pre&Post GnRHa Stim Test), Week 20, Week 24 (Pre&Post GnRHa Stim Test), Week 36 (Pre&Post GnRHa Stim Test), Week 44, and Week 48 (Pre&Post GnRHa Stim Test)

07

Results

Posted May 20, 2020

Participant flow

Participant flow — Overall Study
MilestoneAssigned Intervention
Started64
Completed60
Not completed4

Outcome measures

PrimaryPercentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.

Luteinizing Hormone (LH) suppression is defined as peak-stimulated LH \<4 IU/L. Peak stimulated LH refers to the maximum LH concentration measured 30 minutes after a gonadotropin-releasing hormone agonst (GnRHa) stimulation test.

Time frame:
6 months
Reported as:
Count of participants · Participants
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.
ParticipantsAssigned Intervention
Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months.54
SecondaryPercentage of Subjects With Suppression of Luteinizing Hormone Measured by Blood Levels.

Percentage of subjects with suppressed serum LH concentrations(\<4 IU/L) 30 minutes post GnRHa stimulation test at all assessed timepoints.

Time frame:
Week 12, Week 24, Week 36, and Week 48
Reported as:
Count of participants · Participants
Percentage of Subjects With Suppression of Luteinizing Hormone Measured by Blood Levels.
ParticipantsAssigned Intervention
Visit 3, Week 1251
Visit 5, Week 2454
Visit 6, Week 3650
End of Treatment, Week 4850
SecondaryChanges in Height Velocity (Growth Rate)

Changes in height velocity (growth rate) at all study timepoints after Screening to end of study. Growth velocity is defined for each visit as change from baseline / \[(number of weeks since baseline)/52\]. Week 48: Change from Week 24 growth velocity is defined as change from week 24 to week 48 / \[(number of weeks since week 24)/52\].

Time frame:
Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Reported as:
Mean · cm/year
Changes in Height Velocity (Growth Rate)
cm/yearAssigned Intervention
Visit 2, Week 48.89 ± 13.128
Visit 3, Week 128.30 ± 4.782
Visit 4, Week 206.66 ± 3.155
Visit 5, Week 246.90 ± 3.074
Visit 6, Week 366.48 ± 2.272
Visit 7, Week 446.23 ± 1.953
End of Treatment, Week 486.37 ± 1.893
End of Treatment, Week 48: Change from Week 245.79 ± 2.213
SecondaryBone Age Ratio to Chronological Age at Time of Measurement

Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.

Time frame:
Week 24 and Week 48
Reported as:
Mean · Ratio
Bone Age Ratio to Chronological Age at Time of Measurement
RatioAssigned Intervention
Baseline1.39 ± 0.160
Visit 5, Week 241.34 ± 0.138
End of Treatment, Week 481.32 ± 0.143
Minimum Post-baseline Value1.30 ± 0.138
Maximum Post-baseline Value1.36 ± 0.138
SecondaryPercent Change From Baseline in Height

The percent change from baseline in height at each available post-baseline measurement. Percent change is defined as (((change from Baseline)/(Baseline)) x 100).

Time frame:
Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Reported as:
Mean · Percent change
Percent Change From Baseline in Height
Percent changeAssigned Intervention
Visit 2, Week 40.5 ± 0.78
Visit 3, Week 121.4 ± 0.82
Visit 4, Week 201.9 ± 0.89
Visit 5, Week 242.3 ± 1.06
Visit 6, Week 363.3 ± 1.17
Visit 7, Week 443.9 ± 1.26
End of Treatment, Week 484.3 ± 1.34
SecondaryTanner Scores: Boys - Development of External Genitalia

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Baseline, Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Boys - Development of External Genitalia
Score on a scaleAssigned Intervention
Baseline3.0 ± 0.00
Visit 3, Week 122.5 ± 0.71
Visit 5, Week 242.5 ± 0.71
Visit 6, Week 362.5 ± 0.71
End of Treatment, Week 482.0 ± 0.00
SecondaryTanner Scores: Boys - Development of External Genitalia (Change From Baseline)

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Boys - Development of External Genitalia (Change From Baseline)
Score on a scaleAssigned Intervention
Visit 3, Week 12-0.5 ± 0.71
Visit 5, Week 24-0.5 ± 0.71
Visit 6, Week 36-0.5 ± 0.71
End of Treatment, Week 48-1.0 ± 0.00
SecondaryTanner Scores: Boys and Girls - Pubic Hair

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Baseline, Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Boys and Girls - Pubic Hair
Score on a scaleAssigned Intervention
Baseline2.3 ± 0.81
Visit 3, Week 122.4 ± 0.89
Visit 5, Week 242.5 ± 0.92
Visit 6, Week 362.3 ± 0.94
End of Treatment, Week 482.4 ± 0.95
SecondaryTanner Scores: Boys and Girls - Pubic Hair (Change From Baseline)

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Boys and Girls - Pubic Hair (Change From Baseline)
Score on a scaleAssigned Intervention
Visit 3, Week 120.1 ± 0.56
Visit 5, Week 240.1 ± 0.59
Visit 6, Week 360.1 ± 0.60
End of Treatment, Week 480.1 ± 0.58
SecondaryTanner Scores: Girls - Breast Development

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Baseline, Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Girls - Breast Development
Score on a scaleAssigned Intervention
Baseline3.2 ± 0.61
Visit 3, Week 122.7 ± 0.90
Visit 5, Week 242.6 ± 1.0
Visit 6, Week 362.5 ± 0.89
End of Treatment, Week 482.4 ± 0.93
SecondaryTanner Scores: Girls - Breast Development (Change From Baseline)

Sexual development (physical signs) in puberty were assessed by Tanner staging, a system developed by Marshall and Tanner to categorize pubertal maturation. Tanner stages are commonly used to categorize pubertal maturation in terms of sequence, timing and tempo. Tanner Stages: the minimum is Stage 1 = pre-pubertal physical characteristics and the maximum is Stage 5 = fully matured (adult) physical characteristics.

Time frame:
Week 12, Week 24, Week 36, and Week 48
Reported as:
Mean · Score on a scale
Tanner Scores: Girls - Breast Development (Change From Baseline)
Score on a scaleAssigned Intervention
Visit 3, Week 12-0.5 ± 0.90
Visit 5, Week 24-0.6 ± 0.87
Visit 6, Week 36-0.6 ± 0.86
End of Treatment, Week 48-0.7 ± 0.89
Other pre-specifiedHeight

Height at each available measurement point. Baseline is defined as the last non-missing height measurement collected prior to or on the date of first injection.

Time frame:
Screening, Baseline, Week 4, Week 12, Week 20, Week 24, Week 36, Week 44, and Week 48
Reported as:
Mean · cm
Height
cmAssigned Intervention
Screening136.17 ± 8.292
Baseline136.61 ± 8.071
Visit 2, Week 4137.32 ± 8.201
Visit 3, Week 12138.52 ± 8.284
Visit 4, Week 20138.87 ± 8.070
Visit 5, Week 24139.78 ± 8.206
Visit 6, Week 36140.99 ± 8.374
Visit 7, Week 44141.81 ± 8.268
End of Treatment, Week 48142.37 ± 8.207
Other pre-specifiedBone Age

Bone Age at each available measurement point.

Time frame:
Baseline, Week 24, and Week 48
Reported as:
Mean · years
Bone Age
yearsAssigned Intervention
Baseline11.01 ± 1.307
Visit 5, Week 2411.30 ± 1.238
End of Treatment, Week 4811.65 ± 1.124
Other pre-specifiedBone Age Progression

Bone age progression at each available post-baseline measurement point. Bone age progression is defined as (((change from baseline)/(baseline)) x 100), which is percent change from baseline.

Time frame:
Week 24 and Week 48
Reported as:
Mean · percent change
Bone Age Progression
percent changeAssigned Intervention
Visit 5, Week 242.91 ± 4.607
End of Treatment, Week 486.81 ± 5.741
Minimum Post-Baseline Value2.91 ± 4.607
Maximum Post-Baseline Value6.63 ± 5.736
Other pre-specifiedBone Age Ratio to Chronological Age at Time of Measurement (Percent Change From Baseline)

Bone Age Ratio to Chronological Age at Time of Measurement is bone age/age at bone age assessment.

Time frame:
Week 24 and Week 48
Reported as:
Mean · percent change
Bone Age Ratio to Chronological Age at Time of Measurement (Percent Change From Baseline)
percent changeAssigned Intervention
Visit 5, Week 24-3.25 ± 4.382
End of Treatment, Week 48-4.90 ± 4.689
Minimum Post-baseline Value-6.15 ± 3.934
Maximum Post-baseline Value-1.89 ± 4.155
Other pre-specifiedBone Age Ratio to Chronological Age at Start of Study (Percent Change From Baseline)

Bone age advancement was evaluated relative to chronological age at each given measurement point. Percent change from baseline is: 100 x (the change from baseline value at the post-baseline visit / baseline value).

Time frame:
Week 24 and Week 48
Reported as:
Mean · percent change
Bone Age Ratio to Chronological Age at Start of Study (Percent Change From Baseline)
percent changeAssigned Intervention
Visit 5, Week 242.91 ± 4.607
End of Treatment, Week 486.81 ± 5.741
Minimum Post-baseline Value2.91 ± 4.607
Maximum Post-baseline Value6.63 ± 5.736
Other pre-specifiedBone Age Ratio to Chronological Age at Start of Study

Bone age advancement was evaluated relative to chronological age at each given measurement point. Bone Age Ratio to Chronological Age at Start of Study is bone age/age at first injection.

Time frame:
Baseline, Week 24, and Week 48
Reported as:
Mean · Ratio
Bone Age Ratio to Chronological Age at Start of Study
RatioAssigned Intervention
Baseline1.38 ± 0.158
Visit 5, Week 241.42 ± 0.153
End of Treatment, Week 481.47 ± 0.178
Minimum Post-baseline Value1.42 ± 0.153
Maximum Post-baseline Value1.47 ± 0.176
Other pre-specifiedGnRH Antagonist Evaluation

GnRH Antagonist Evaluation occurred for the two week period following each treatment and at each visit to assess flare symptoms. The percent of subjects who affirm (or whose parent/guardian affirms) each symptom domain in the global interview.

Time frame:
Week 2, Week 4, Week 12, Week 20, Week 24, Week 26, Week 36, Week 44, and Week 48
Reported as:
Count of participants · Participants
GnRH Antagonist Evaluation
ParticipantsAssigned Intervention
Telephone Contact #1, Week 2 — Any GnRH Antagonist Conditions Reported?15
Telephone Contact #1, Week 2 — Flare or hot flashes4
Telephone Contact #1, Week 2 — Injection site reactions11
Telephone Contact #1, Week 2 — Burning/Stinging0
Telephone Contact #1, Week 2 — Pain9
Telephone Contact #1, Week 2 — Bruising3
Telephone Contact #1, Week 2 — Redness0
Telephone Contact #1, Week 2 — Difficulty in urination1
Telephone Contact #1, Week 2 — Bone Pain1
Telephone Contact #1, Week 2 — Aggravation of weakness or other muscle symptoms0
Telephone Contact #1, Week 2 — Onset of Allergic reactions0
Telephone Contact #1, Week 2 — No GnRH Antagonist conditions reported?15
Visit 2, Week 4 — Any GnRH Antagonist Conditions Reported?4
Visit 2, Week 4 — Flare or hot flashes2
Visit 2, Week 4 — Injection site reactions1
Visit 2, Week 4 — Burning/Stinging0
Visit 2, Week 4 — Pain1
Visit 2, Week 4 — Bruising0
Visit 2, Week 4 — Redness0
Visit 2, Week 4 — Difficulty in urination0
Visit 2, Week 4 — Bone Pain1
Visit 2, Week 4 — Aggravation of weakness or other muscle symptoms0
Visit 2, Week 4 — Onset of Allergic reactions0
Visit 2, Week 4 — No GnRH Antagonist conditions reported?53
Visit 3, Week 12 — Any GnRH Antagonist Conditions Reported?5
Visit 3, Week 12 — Flare or hot flashes1
Visit 3, Week 12 — Injection site reactions3
Visit 3, Week 12 — Burning/Stinging0
Visit 3, Week 12 — Pain2
Visit 3, Week 12 — Bruising0
Visit 3, Week 12 — Redness1
Visit 3, Week 12 — Difficulty in urination0
Visit 3, Week 12 — Bone Pain1
Visit 3, Week 12 — Aggravation of weakness or other muscle symptoms0
Visit 3, Week 12 — Onset of Allergic reactions0
Visit 3, Week 12 — No GnRH Antagonist conditions reported?48
Visit 4, Week 20 — Any GnRH Antagonist Conditions Reported?3
Visit 4, Week 20 — Flare or hot flashes1
Visit 4, Week 20 — Injection site reactions1
Visit 4, Week 20 — Burning/Stinging0
Visit 4, Week 20 — Pain1
Visit 4, Week 20 — Bruising0
Visit 4, Week 20 — Redness0
Visit 4, Week 20 — Difficulty in urination0
Visit 4, Week 20 — Bone Pain1
Visit 4, Week 20 — Aggravation of weakness or other muscle symptoms0
Visit 4, Week 20 — Onset of Allergic reactions0
Visit 4, Week 20 — No GnRH Antagonist conditions reported?53
Visit 5, Week 24 — Any GnRH Antagonist Conditions Reported?3
Visit 5, Week 24 — Flare or hot flashes1
Visit 5, Week 24 — Injection site reactions1
Visit 5, Week 24 — Burning/Stinging0
Visit 5, Week 24 — Pain0
Visit 5, Week 24 — Bruising0
Visit 5, Week 24 — Redness0
Visit 5, Week 24 — Difficulty in urination0
Visit 5, Week 24 — Bone Pain1
Visit 5, Week 24 — Aggravation of weakness or other muscle symptoms0
Visit 5, Week 24 — Onset of Allergic reactions0
Visit 5, Week 24 — No GnRH Antagonist conditions reported?55
Telephone Contact #2, Week 26 — Any GnRH Antagonist Conditions Reported?16
Telephone Contact #2, Week 26 — Flare or hot flashes2
Telephone Contact #2, Week 26 — Injection site reactions15
Telephone Contact #2, Week 26 — Burning/Stinging0
Telephone Contact #2, Week 26 — Pain15
Telephone Contact #2, Week 26 — Bruising0
Telephone Contact #2, Week 26 — Redness3
Telephone Contact #2, Week 26 — Difficulty in urination0
Telephone Contact #2, Week 26 — Bone Pain0
Telephone Contact #2, Week 26 — Aggravation of weakness or other muscle symptoms0
Telephone Contact #2, Week 26 — Onset of Allergic reactions0
Telephone Contact #2, Week 26 — No GnRH Antagonist conditions reported?6
Visit 6, Week 36 — Any GnRH Antagonist Conditions Reported?3
Visit 6, Week 36 — Flare or hot flashes1
Visit 6, Week 36 — Injection site reactions1
Visit 6, Week 36 — Burning/Stinging0
Visit 6, Week 36 — Pain1
Visit 6, Week 36 — Bruising0
Visit 6, Week 36 — Redness1
Visit 6, Week 36 — Difficulty in urination1
Visit 6, Week 36 — Bone Pain0
Visit 6, Week 36 — Aggravation of weakness or other muscle symptoms0
Visit 6, Week 36 — Onset of Allergic reactions0
Visit 6, Week 36 — No GnRH Antagonist conditions reported?51
Visit 7, Week 44 — Any GnRH Antagonist Conditions Reported?3
Visit 7, Week 44 — Flare or hot flashes2
Visit 7, Week 44 — Injection site reactions0
Visit 7, Week 44 — Burning/Stinging0
Visit 7, Week 44 — Pain0
Visit 7, Week 44 — Bruising0
Visit 7, Week 44 — Redness0
Visit 7, Week 44 — Difficulty in urination0
Visit 7, Week 44 — Bone Pain0
Visit 7, Week 44 — Aggravation of weakness or other muscle symptoms0
Visit 7, Week 44 — Onset of Allergic reactions1
Visit 7, Week 44 — No GnRH Antagonist conditions reported?53
End of Treatment, Week 48 — Any GnRH Antagonist Conditions Reported?1
End of Treatment, Week 48 — Flare or hot flashes1
End of Treatment, Week 48 — Injection site reactions0
End of Treatment, Week 48 — Burning/Stinging0
End of Treatment, Week 48 — Pain0
End of Treatment, Week 48 — Bruising0
End of Treatment, Week 48 — Redness0
End of Treatment, Week 48 — Difficulty in urination0
End of Treatment, Week 48 — Bone Pain0
End of Treatment, Week 48 — Aggravation of weakness or other muscle symptoms0
End of Treatment, Week 48 — Onset of Allergic reactions0
End of Treatment, Week 48 — No GnRH Antagonist conditions reported?57
Other pre-specifiedPercentage of Subjects With Suppression of FSH, Estradiol, Oestradiol (HS), and Testosterone Measured by Blood Levels.

The percentage of subjects with FSH, estradiol and testosterone suppression to prepubertal levels (FSH \< 2.5 mIU/mL, estradiol \< 20 pg/mL and testosterone \< 28.4 ng/dL) at each available time point.

Time frame:
Week 12, Week 24, Week 36, and Week 48
Reported as:
Count of participants · Participants
Percentage of Subjects With Suppression of FSH, Estradiol, Oestradiol (HS), and Testosterone Measured by Blood Levels.
ParticipantsAssigned Intervention
Visit 3, Week 12 : FSH37
Visit 3, Week 12 : Estradiol58
Visit 3, Week 12 : Oestradiol (HS)56
Visit 3, Week 12 : Testosterone2
Visit 5, Week 24 : FSH41
Visit 5, Week 24 : Estradiol59
Visit 5, Week 24 : Oestradiol (HS)58
Visit 5, Week 24 : Testosterone2
Visit 6, Week 36 : FSH26
Visit 6, Week 36 : Estradiol57
Visit 6, Week 36 : Oestradiol (HS)56
Visit 6, Week 36 : Testosterone2
End of Treatment, Week 48 : FSH32
End of Treatment, Week 48 : Estradiol56
End of Treatment, Week 48 : Oestradiol (HS)55
End of Treatment, Week 48 : Testosterone1
Other pre-specifiedChanges in the Ratio of LH/FSH

Changes in ratio of LH/FSH at each time point from Screening to End of Study

Time frame:
Screening (Pre&Post GnRHa Stim Test), Baseline (0,1,4,6 hours Post-Injection), Week 4, Week 12 (Pre&Post GnRHa Stim Test), Week 20, Week 24 (Pre&Post GnRHa Stim Test), Week 36 (Pre&Post GnRHa Stim Test), Week 44, and Week 48 (Pre&Post GnRHa Stim Test)
Reported as:
Mean · Ratio
Changes in the Ratio of LH/FSH
RatioAssigned Intervention
Screening: Pre GnRHa Stimulation Test0.387 ± 0.4675
Screening: Post GnRHa Stimulation Test2.187 ± 1.6713
Baseline0.604 ± 0.9851
Baseline: 1 hr Post Inj2.424 ± 2.1534
Baseline: 1 hr Post Inj: Change from Baseline1.856 ± 1.7277
Baseline: 4 hr Post Inj2.110 ± 2.3939
Baseline: 4 hr Post Inj: Change from Baseline1.542 ± 2.0932
Baseline: 6 hr Post Inj1.691 ± 1.7330
Baseline: 6 hr Post Inj: Change from Baseline1.123 ± 1.4378
Week 40.843 ± 1.0004
Week 4: Change from Baseline0.233 ± 1.1425
Week 12: Pre GnRHa Stim Test0.565 ± 0.9100
Week 12: Pre GnRHa Stim Test: Change from Baseline-0.050 ± 1.0423
Week 12: Post GnRHa Stim Test1.342 ± 1.7934
Week12: Post GnRHa Stim Test: Change from Baseline0.721 ± 1.7237
Week 200.654 ± 0.9806
Week 20: Change from Baseline0.068 ± 1.1859
Week 24: Pre GnRHa Stim Test0.611 ± 0.9571
Week 24: Pre GnRHa Stim Test: Change from Baseline0.007 ± 1.1818
Week 24: Post GnRHa Stim Test1.320 ± 1.2843
Week24: Post GnRHa Stim Test: Change from Baseline0.716 ± 1.4450
Week 36: Pre GnRHa Stim Test0.474 ± 0.5249
Week 36: Pre GnRHa Stim Test: Change from Baseline-0.125 ± 1.0038
Week 36: Post GnRHa Stim Test1.051 ± 1.4130
Week36: Post GnRHa Stim Test: Change from Baseline0.461 ± 15374
Week 440.517 ± 0.7846
Week 44: Change from Baseline-0.073 ± 1.0575
Week 48: Pre GnRHa Stim Test0.557 ± 1.0957
Week 48: Pre GnRHa Stim Test: Change from Baseline-0.033 ± 1.2191
Week 48: Post GnRHa Stim Test1.092 ± 1.5655
Week48: Post GnRHa Stim Test: Change from Baselin0.509 ± 1.5780

Adverse events

Collected over Adverse events were collected from the time ICF was signed until End of Treatment (48 weeks). Any AEs related to study drug were followed for 28 days or through resolution, stabilization, until deemed clinically insignificant, or until the subject is lost to follow-up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Assigned Intervention0/64 (0%)1/64 (1.6%)55/64 (85.9%)
Most frequent serious events
Most frequent serious events
EventAssigned Intervention
WheezingRespiratory, thoracic and mediastinal disorders1/64
RashSkin and subcutaneous tissue disorders1/64
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAssigned Intervention
NasopharyngitisInfections and infestations14/64
PyrexiaGeneral disorders11/64
HeadacheNervous system disorders10/64
CoughRespiratory, thoracic and mediastinal disorders8/64
Abdominal painGastrointestinal disorders6/64
NauseaGastrointestinal disorders5/64
ConstipationGastrointestinal disorders4/64
VomitingGastrointestinal disorders4/64
Upper respiratory tract infectionInfections and infestations4/64
BronchospasmRespiratory, thoracic and mediastinal disorders4/64

Baseline characteristics

Age, Continuous
Age, Continuous(years)Assigned Intervention
Mean7.5 ± 0.89
Sex: Female, Male
Sex: Female, Male(Participants)Assigned Intervention
Female62
Male2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Assigned Intervention
American Indian or Alaska Native5
Asian3
Black or African American15
Native Hawaiian or Other Pacific Islander1
White34
Unwilling to Provide1
Other5
Hispanic or Latino36
Not hispanic or Latino28
Region of Enrollment
Region of Enrollment(participants)Assigned Intervention
New Zealand2
Canada2
Argentina13
United States31
Mexico7
Chile9
Luteinizing Hormone
Luteinizing Hormone(IU/L)Assigned Intervention
Mean23.46 ± 24.282
08

Study locations

20 sites
  • University of California, San Diego
    San Diego, California 92123, United States
  • Joe DiMaggio Children's Hospital
    Hollywood, Florida 33021, United States
  • Nemours Children's Clinic
    Jacksonville, Florida 32207, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • University of Minnesota
    Minneapolis, Minnesota 55414, United States
  • Cincinnati Children's Hospital Medical Center, Endocrine
    Cincinnati, Ohio 45229, United States
  • University of Oklahoma College of Medicine
    Tulsa, Oklahoma 74135, United States
  • Seattle Children's
    Seattle, Washington 98105, United States
  • MultiCare Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Hospital de Ninos
    Buenos Aires, C1425EFD, Argentina
  • University of Calgary, Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • CHU de Quebec-Universite Laval
    Quebec, G1V 4G2, Canada
  • Pontificia Universidad Catolica de Chile
    Santiago, Metropolitana 8330074, Chile
  • Instituto de Investigaciones Materno Infantil (IDIMI)
    Santiago, Metropolitana 8360160, Chile
  • Hospital Regional de Antofagasta Leonardo Guzman
    Antofagasta, Second Region 1270001, Chile
  • Hospital Unversitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo Leon 64460, Mexico
  • Instituto de Investigaciones Aplicadas a la Neurociencia, A.C.
    Durango, 34000, Mexico
  • The Liggins Institute, University of Auckland
    Auckland, 1023, New Zealand
09

References and documents

Publications

  • Klein KO, Freire A, Gryngarten MG, Kletter GB, Benson M, Miller BS, Dajani TS, Eugster EA, Mauras N. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty. J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3660-71. doi: 10.1210/clinem/dgaa479. Erratum In: J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2842. doi: 10.1210/clinem/dgab294. PubMed 32738042 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2018, 36 months.

Results were first posted in May 2020, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2015
First posted
May 25, 2015
StartActual
Aug 31, 2015
Primary completionActual
Sep 5, 2018
CompletionActual
Sep 5, 2018
Results first posted
May 20, 2020
Last update
Jun 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02452931
Lead sponsor
Tolmar Inc.
Responsible party
Sponsor
First posted
May 25, 2015
Start date
Aug 31, 2015
Primary completion
Sep 5, 2018
Completion
Sep 5, 2018
Results posted
May 20, 2020
Last update
Jun 2, 2020

Study contacts

Peggy Schorr
study director · orphan reach USA, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion